menu
    • menu
    [{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvidia Therapeutics Announces Publication in Science Translational Medicine of Strategy for Lowering Triglycerides Using a Mimetic Peptide","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"D6PV","moa":"Apolipoprotein C-III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Corvidia Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvidia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Corvidia T.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 1701963","moa":"SOS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ FORMA Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Announces Publication of Olutasidenib\u2019s Molecular Design and Potential Utility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation and Rare Pediatric Disease Designation for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"NewCo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FORMA Therapeutics Announces Divestiture of Select Hit Discovery Capabilities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Divestment","leadProduct":"FT-4202","moa":"RBC pyruvate kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ NewCo","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Receives Orphan Drug Designation From FDA for DCR-A1AT ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DCR-A1AT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Receives FDA Orphan Drug Designation for FT-4202 for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity of a Potent and Selective Inhibitor of CBP\/p300","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-6876","moa":"CBP\/p300","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s First Semaglutide Obesity Trial Hits The Mark","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Clinical Data to be Presented at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Provides Initial Observations From PHYOX 3 Trial of Nedosiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk To Present New Data at the 80th Annual American Diabetes Association Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Reports Weight Loss of 14.9% (16.9% if taken as intended) in STEP 1 trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Corvidia Therapeutics","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"$725.0 million","newsHeadline":"Novo Nordisk to Acquire Corvidia Therapeutics to Expand Cardiovascular Presence","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Ziltivekimab","moa":"IL-6","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novo Nordisk","amount2":2.1000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational, Once-Weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-Daily Insulin Glargine U100 In Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Receives Rare Pediatric Disease Designation From U.S.FDA for Nedosiran for Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Successfully Completes AM833 Phase 2 Trial and Phase 1 Combination Trial with AM833 and Semaglutide in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fleroxacin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rybelsus\u00ae approved in Japan for the treatment of type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Staten Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Staten Biotechnology, In Collaboration with Novo Nordisk, Starts Dosing of Anti-ApoC3 Antibody SST-5058 in First-in-Human Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SST-5058","moa":"apoC3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Resumes the Phase 3 Clinical Trials Investigating Concizumab (Anti-Tfpi Mab) In Haemophilia A and B With or without Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Launch for Novo's New Diabetes Pill","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Switching to Novo Nordisk's Investigational Insulin Icodec Found to be Efficacious in People with Type 2 Diabetes in Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Enters into a License Agreement for Chugai\u2019s Antibody Engineering Technologies with Novo Nordisk","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Presents New Interim Data From PHYOX\u21223 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Positive Top-Line Olutasidenib Data From A Planned Interim Analysis Of A Registrational Phase 2 Clinical Trial In AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Completed the Phase 2b Trial with Ziltivekimab in Cardiovascular Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented at AASLD","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Four Oral and Poster Presentations on FT-4202 in Sickle Cell Disease at 2020 ASH Virtual Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 to Treat Chronic Hepatitis B at AASLD\u2019s The Liver Meeting 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo's Once-Weekly Semaglutide 2.0 mg Shows Superior Reduction in HbA1c vs Once-Weekly Semaglutide 1.0 mg in Type 2 Diabetes Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Files for US FDA Regulatory Approval of Once-Weekly Semaglutide 2.4 mg For Weight Management","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents Clinical Proof-of-Concept Data Supporting the Potential of FT-4202 to Treat Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Announces Completion of the Emisphere Technologies Acquisition","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":1.8,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Forma Therapeutics Launches Proposed Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"FT-4202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk to Acquire Emisphere Technologies and Obtain Ownership of the Eligen\u00ae SNAC Oral Delivery Technology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":1.8,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk To Enter Phase 3 Development in Alzheimer\u2019s Disease with Oral Semaglutide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Files for EU Regulatory Approval of Once-Weekly Semaglutide 2.0 mg For the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Files for Regulatory Approval in the US of Once-Weekly Semaglutide 2.0 Mg for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Sogroya Moves Closer Towards EU Approval","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Initiates PHYOX\u21224 Trial of Nedosiran for Primary Hyperoxaluria Type 3","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Semaglutide Injection Effective in Weight Loss Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Dosed First Patient in Phase 1 Clinical Trial Evaluating FT-7051 Metastatic Castration-resistant Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"FT-7051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead and Novo Nordisk Expand NASH Clinical Collaboration","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Receives Refusal to File Letter for Once-Weekly Semaglutide 2.0 mg For the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"$180.0 million","newsHeadline":"Royalty Pharma Acquires Oxlumo\u2122 Royalty Interest from Dicerna for up to $240 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Lumasiran","moa":"HO-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Dicerna Pharmaceuticals","amount2":0.23999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk to Initiate Phase 3a Development in Obesity With Oral Semaglutide","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dicerna Announces Boehringer Ingelheim\u2019s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"DCR-LIV2","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Dicerna Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Ziltivekimab Hits Primary Endpoint in CKD Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ziltivekimab","moa":"Il-6","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Resubmits Once-Weekly Semaglutide 2.0 mg For the Treatment of Type 2 Diabetes for US Regulatory Approval","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Heartseed","pharmaFlowCategory":"D","amount":"$598.0 million","upfrontCash":"$55.0 million","newsHeadline":"Heartseed and Novo Nordisk Enter Into Global Collaboration and Licence Agreement for Stem Cell-Based Therapy for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Allogeneic iPSC-derived Cardiomyocytes","moa":"Angiogenic factors secretion","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0.59999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"Intramyocardial Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents New Phase 1 Data on Etavopivat at 26th European Hematology Association Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 (Semaglutide 2.4 mg), the First and Only Once-Weekly Glp-1 Therapy for Weight Management, Approved in the US","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Lumen Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience and Novo Nordisk Collaborate to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational 2.0 mg Dose of Ozempic\u00ae (Semaglutide) Demonstrates Superior Reductions in Blood Sugar vs Ozempic\u00ae 1.0 Mg","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Begins Patient Dosing in ESTRELLA Phase 2 Trial of Belcesiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Belcesiran","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Prothena","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$100.0 million","newsHeadline":"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"PRX004","moa":"ATTR protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novo Nordisk","amount2":1.2,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.2,"dosageForm":"Intravenous Infusion","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Hemab Therapeutics","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo US$ 55M Series A Generation Therapeutics for BleedingThrombosis Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"Monoclonal-bispecific Antibody-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0.059999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Reports Positive Top-Line Results From PHYOX\u21222 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Veristat Inc","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Wants Partner to Sell Nedosiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC\u2122 RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"DCR-A1203","moa":"ALDH2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics\u2019 FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"FT-7051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Results for PHYOX\u21224, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Presents PHYOX\u21222 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"PathAI, inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PathAI And Novo Nordisk Present AI-Powered Scoring Showing Significant Reduction of Fibrosis Following Semaglutide Treatment in Patients With NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 Recommended for Approval for The Treatment of Obesity by The European Regulatory Authorities","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Belcesiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Dicerna Pharmaceuticals","pharmaFlowCategory":"D","amount":"$3,300.0 million","upfrontCash":"$3,300.0 million","newsHeadline":"Novo Nordisk to Acquire Dicerna","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"DCR-NOVO1","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":3.2999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":3.2999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics\u2019 Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics\u2019 Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$5.0 million","newsHeadline":"2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"MegaTAL mRNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Eracal Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EraCal Therapeutics Enters into Research Collaboration with Novo Nordisk","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Massachusetts Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Biologic Medicine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Massachusetts Institute of Technology","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ozempic\u00ae 2.0 mg Approved in the US for the Treatment of Type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novoseven\u00ae Recommended for Approval for the Treatment of Severe Postpartum Haemorrhage by the European Medicines Agency","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Eptacog Alfa","moa":"Coagulation cascade","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-weekly Insulin Icodec Demonstrates Superior Reduction in HBA1c Vs Insulin Degludec in People With Type 2 Diabetes in Onwards 2 Phase 3A Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk and Flagship Pioneering Announce a Strategic Collaboration to Create a Portfolio of Transformational Medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"FT-7051","moa":"CBP\/p300","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Achieves Primary Objectives of Onwards 1 and 6 Trials With Once-weekly Insulin Icodec Demonstrating Superior Reduction in Hba1c Vs Insulin Glargine U100 in Onwards 1","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Presentations at Upcoming Hematology Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk a\/s: Sogroya\u00ae Data Show Potential as Once-weekly Treatment in Children Living With Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Data for Concizumab Show 86% Reduction in Treated Bleeds in Haemophilia a or B With Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mim8 Phase 1 & 2 Data Demonstrates Potential as Once Monthly Treatment for People With Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Mim8","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Achieves Primary Objectives of ONWARDS 3 and 4 Trials With Once-weekly Insulin Icodec Demonstrating Superior Reduction in HbA1c Vs Insulin Degludec in ONWARDS 3","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Divestment","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novo Nordisk","amount2":0.11,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"$2.0 million","newsHeadline":"Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Olutasidenib","moa":"IDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Successfully Completes Phase 2 Trial With Cagrisema in People With Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$92.3 million","newsHeadline":"Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris Set to Regain Full Rights to Macrilen\u2122 (Macimorelin) in U.S. and Canada from Novo Nordisk","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Termination","leadProduct":"Macimorelin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Zealand Pharma","pharmaFlowCategory":"D","amount":"$39.2 million","upfrontCash":"$3.4 million","newsHeadline":"Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE\u00ae (dasiglucagon)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"More People With Type 2 Diabetes Achieved Blood Sugar Target With Once-weekly Insulin Icodec Compared With Once-daily Insulin Degludec","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-Weekly Insulin Icodec Demonstrates Superior Reduction In HbA1c In Combination With A Dosing Guide App Versus Once-daily Basal Insulin In People With Type 2 Diabetes In ONWARDS 5 Phase 3a Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ventus Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Chief Scientific Officer Michael Crackower, Ph.D., to Present on ReSOLVE\u2122 Platform at Next Generation Undruggable Conference","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VENT-01","moa":"NLRP3","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Forma Therapeutics","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Novo Nordisk Announces the Completion of The Forma Therapeutics Acquisition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Novo Nordisk","amount2":1.1000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":1.1000000000000001,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Prothena","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$100.0 million","newsHeadline":"Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004\/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"NNC6019","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novo Nordisk","amount2":1.2,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.2,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ventus Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VENT-03","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Announces FDA Approval of Label Update for Rybelsus\u00ae (semaglutide) Allowing Use as A First-Line Option for Adults with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Novo Nordisk to Acquire Forma Therapeutics and Expand Presence in Sickle Cell Disease and Rare Blood Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Novo Nordisk","amount2":1.1000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":1.1000000000000001,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ventus Therapeutics","pharmaFlowCategory":"D","amount":"$703.0 million","upfrontCash":"$70.0 million","newsHeadline":"Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"VENT-01","moa":"NLRP3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Novo Nordisk","amount2":0.69999999999999996,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Extends Their DNA Damage Repair Footprint With New Oncology Pipeline Entry","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"FT-3171","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Diabeloop","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diabeloop Announces Collaboration With Novo Nordisk to Pursue Its Interoperability Strategy With Connected Insulin Pens","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Dewpoint Therapeutics","pharmaFlowCategory":"D","amount":"$745.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dewpoint Therapeutics Partners With Novo Nordisk To Explore The Field Of Biomolecular Condensates To Treat Insulin Resistance And Diabetes Progression","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.75,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.75,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Semaglutide 25 mg and 50 mg Demonstrate Superior Reductions in Hb A1c and Body Weight versus 14 mg in People with Type 2 Diabetes in The PIONEER PLUS Phase 3 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Aspect Biosystems","pharmaFlowCategory":"D","amount":"$2,675.0 million","upfrontCash":"$75.0 million","newsHeadline":"Aspect Biosystems And Novo Nordisk Enter Partnership To Develop Bioprinted Tissue Therapeutics For Diabetes And Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Bioprinted-based Tissue Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":2.6800000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.6800000000000002,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Alhemo, the First Subcutaneous Prophylactic Treatment for People Living with Hemophilia B with Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Concizumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Semaglutide 50 mg Achieved 15.1% Weight Loss (17.4% if all People Adhered to Treatment) in Adults with Obesity or Overweight in the OASIS 1 Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$5.0 million","newsHeadline":"2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Pathos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP\/p300 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"P-300","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novo Nordisk \/ Pathos","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Life Edit Therapeutics","pharmaFlowCategory":"D","amount":"$1,920.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Novo Nordisk","amount2":1.9199999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1.9199999999999999,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-weekly Sogroya\u00ae (somapacitan) Receives CHMP Positive Opinion for Expanded use in Children and Adolescents With Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Semaglutide 2.4 mg Reduces the Risk of Major Adverse Cardiovascular Events by 20% in Adults with Overweight or Obesity in the SELECT Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inversago Pharma","pharmaFlowCategory":"D","amount":"$1,075.0 million","upfrontCash":"$1,075.0 million","newsHeadline":"Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and Other Serious Metabolic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"INV-202","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":1.0800000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pottsville Residents with Non-Alcoholic Steatohepatitis (NASH) Liver Disease Can Now Join New Research Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Semaglutide 2.4 mg Shows Large Reductions in Heart Failure-Related Symptoms and Physical Limitations in People with Heart Failure with Preserved Ejection Fraction and Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$511.1 million","upfrontCash":"$16.2 million","newsHeadline":"Novo Nordisk Acquires Embark Biotech, Including its Lead Asset Targeting Obesity and Other Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0.51000000000000001,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Valo Health","pharmaFlowCategory":"D","amount":"$2,760.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valo Health and Novo Nordisk to Collaborate to Discover and Develop Novel Treatments for Cardiometabolic Diseases Using Human Data and Artificial Intelligence","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":2.7599999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.7599999999999998,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk and Evotec Collaborate to Launch LAB eN\u00b2, a Translational Drug Discovery Accelerator, to Address Innovation Gap in Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Will Stop the Once-weekly Injectable Semaglutide Kidney Outcomes Trial, FLOW, Based on Interim Analysis","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"KBP Biosciences","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk to Acquire Ocedurenone for Uncontrolled Hypertension from KBP Biosciences","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Ocedurenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":1.3,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":1.3,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Rivfloza\u2122 for Children \u22659 Years Old and Adults Living with Primary Hyperoxaluria Type 1 (PH1), a Rare Genetic Condition","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nedosiran","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Omega Therapeutics","pharmaFlowCategory":"D","amount":"$532.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.53000000000000003,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Cellarity","pharmaFlowCategory":"D","amount":"$532.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.53000000000000003,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Eracal Therapeutics","pharmaFlowCategory":"D","amount":"$255.0 million","upfrontCash":"Undisclosed","newsHeadline":"EraCal Therapeutics Enters into a Collaboration and License Agreement with Novo Nordisk","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.26000000000000001,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall Licenses an Anti-IL-21 Monoclonal Antibody from Novo Nordisk to Develop it as a First-in-Class Agent in Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NN-8828","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Neomorph","pharmaFlowCategory":"D","amount":"$1,460.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":1.46,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":1.46,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Awiqli\u00ae (once-weekly basal insulin icodec) Recommended for Approval for The Treatment of Diabetes by The European Regulatory Authorities","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Cardior Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"CDR132L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":1.1100000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":1.1100000000000001,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Launches Obesity Treatment Wegovy in Japan","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk A\/S: Semaglutide 1.0 mg Demonstrates 24% Reduction in the Risk of Kidney Disease-related Events in People with Type 2 Diabetes and Chronic Kidney Disease in the FLOW trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Obesity Pill Bests Wegovy in Early Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Amycretin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u00ae Receives FDA approval for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"NNC6022-0001","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Metaphore Biotechnologies","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0.59999999999999998,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk A\/S: Once-weekly and Once-monthly Mim8 Demonstrate Superior Reduction of Treated Bleeding Episodes Compared to On-Demand and Prior Prophylaxis Treatment in People with Haemophilia a In the Frontier 2 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mim8","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA panel votes against Novo Nordisk's weekly insulin in type 1 diabetes patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Biosplice","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosplice, Novo Nordisk Partner to Develop Drug Candidates for Treatment of Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"2seventy bio Sells Hemophilia A Candidate and MegaTAL Technology to Novo Nordisk for $40M","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Divestment","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ocedurenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mim8 Show Superior Reduction in Bleeding Rate Compared to Prior Treatment in Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mim8","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA declines to approve Novo Nordisk's weekly insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Authority Adopts Update to Wegovy\u00ae Label for Cardiovascular Risk Reduction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk launches weight-loss drug Wegovy in Australia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."}]

    Find Clinical Drug Pipeline Developments & Deals by Novo Nordisk

    Menu

    Novo Nordisk

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk launches weight-loss drug Wegovy in Australia

                            Details : Wegovy (semaglutide) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management & treatment of obesity.

                            Product Name : Wegovy

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            August 02, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Authority Adopts Update to Wegovy® Label for Cardiovascular Risk Reduction

                            Details : Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to reduce the risk of major adverse cardiovascular events in adults.

                            Product Name : Wegovy

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            July 25, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Icodec

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US FDA declines to approve Novo Nordisk's weekly insulin

                            Details : Awiqli (insulin icodec) is a once-weekly basal insulin analogue, which is being evaluated for the treatment of patients with Diabetes Mellitus, Type 2 & Type 1.

                            Product Name : Awiqli

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            July 10, 2024

                            Lead Product(s) : Insulin Icodec

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : 2Seventy Bio

                            Deal Size : $40.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            2seventy bio Sells Hemophilia A Candidate and MegaTAL Technology to Novo Nordisk for $40M

                            Details : Novo has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 26, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : 2Seventy Bio

                            Deal Size : $40.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ocedurenone

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss

                            Details : KBP-5074 (ocedurenone) is a non-steroidal, mineralocorticoid receptor antagonist, was in development for patients with uncontrolled hypertension in patients with advanced chronic kidney disease.

                            Product Name : KBP-5074

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 26, 2024

                            Lead Product(s) : Ocedurenone

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy

                            Details : NovoCare (semaglutide) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management & treatment of obesity.

                            Product Name : NovoCare

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            June 26, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mim8

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mim8 Show Superior Reduction in Bleeding Rate Compared to Prior Treatment in Haemophilia A

                            Details : NNC0365-3769 (Mim8) is a next-generation FVIIIa mimetic antibody delivering haemostasis for once-weekly or once-monthly prophylaxis for people living with haemophilia A, with and without inhibitors.

                            Product Name : NNC0365-3769

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 23, 2024

                            Lead Product(s) : Mim8

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Biosplice

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biosplice, Novo Nordisk Partner to Develop Drug Candidates for Treatment of Diabetes

                            Details : The collaboration combines Novo Nordisk’s expertise in diabetes and Biosplice’s research and development efforts focused on creating selective and potent DYRK inhibitors.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 13, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Biosplice

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Icodec

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US FDA panel votes against Novo Nordisk's weekly insulin in type 1 diabetes patients

                            Details : Awiqli (insulin icodec) is a once-weekly basal insulin analogue , which is being evaluated for the treatment of patients with Diabetes Mellitus, Type 2 & Type 1.

                            Product Name : Awiqli

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            May 24, 2024

                            Lead Product(s) : Insulin Icodec

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial

                            Details : Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as Novo's Wegovy, slowed the worsening of kidney dysfunction in patients with type 2 diabetes.

                            Product Name : Ozempic

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            May 24, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth